logo
logo

Surge Therapeutics Raises $26M Series A Financing To Accelerate Development Of Intraoperative Immunotherapy To Improve Survival Outcomes Post-Surgery

Oct 17, 2022•over 2 years ago

Amount Raised

$26 Million

Round Type

series a

CambridgeBiotechnologyHealth CareTherapeutics

Description

SURGE Therapeutics (SURGE) today announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, Alumni Ventures, and the Cancer Research Institute. The funds will be used to accelerate development of the SURGETM intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.

Company Information

Company

SURGE Therapeutics

Location

Cambridge, Maryland, United States

About

SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People